Blueprint Medicines Profile

87.49
USD 0.53  0.6%
96%
56%

Sale by Marion Dorsch of 4750 shares of Blueprint Medicines

Blueprint Medicines Corporation insider trading alert for sale of common stock by Marion Dorsch, Chief Scientific Officer, on February 15, 2018. This event was filed by Blueprint Medicines Corp with SEC on 2017-11-22. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Blueprint Medicines Summary

Blueprint Medicines Corporation (BPMC) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 133 people. Blueprint Medicines is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 3.49 B. Blueprint Medicines Corporation conducts business under Healthcare sector and is part of Biotechnology industry. This company has 42.88 M outstanding shares of which 2.17 M shares are currently shorted by private and institutional investors with about 5.59 trading days to cover. N/A currently holds about 390.65 M in cash with (103.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.97.
Check Blueprint Medicines Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Blueprint Medicines Corporation Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Blueprint Medicines Against Markets

Risk Adjusted
Performance Score (0 to 100)
6 
Chance of
Financial Distress (0 to 100%)
< 27% 
Equity ratings for Blueprint Medicines Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 133 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameBlueprint Medicines Corporation
President CEO, DirectorJeffrey AlbersAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationMASSACHUSETTS, U.S.A
Business Address38 Sidney Street
ExchangeNASDAQ
CIK Number01597264.0
CUSIP09627Y109
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.blueprintmedicines.com
Contact Number617 374 7580
CurrencyUSD - US Dollar

Current Sentiment - BPMC

Blueprint Medicines Investor Sentiment
Most of Macroaxis users are currently bullish on Blueprint Medicines Corporation. What is your opinion about investing in Blueprint Medicines Corporation? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip  Hide

Recommendations

Blueprint Medicines Analyst Recommendations
Target PriceAdvice# of Analysts
40.5Buy4Odds
Blueprint Medicines Corporation current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Blueprint Medicines Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Blueprint Medicines Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.71March 10, 2017
Blueprint Medicines Corporation normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Blueprint Medicines Corporate Directors
Nicholas Lydon Director, Ph.D
Charles Rowland Independent Director, MBA
Michael Landsittel Interim Principal Accounting and Financial Officer and Sr. Director of Fin., MBA